Drug Discovery

1. Rheumatology Group

   1. Indomethacin

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 209-219

   2. d-Penicillamine

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 221-233

   3. Hydroxychloroquine

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 235-247

   4. Methotrexate

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 249-263

   5. Cyclophosphamide

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 265-280

2. Anesthesiology Group

   1. Front Matter

      Pages 281-281

      PDF

   2. Succinylcholine

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 283-296

   3. Halothane

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 297-305

   4. Fentanyl

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 307-318

   5. Naloxone

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 319-330

3. Pulmonary Group

   1. Front Matter

      Pages 331-331

      PDF

   2. Albuterol

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 333-348

   3. Beclomethasone Dipropionate

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 349-362

4. Gastrointestinal Group

   1. Front Matter

      Pages 363-363

      PDF

   2. Cimetidine

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 365-376

   3. Chenodeoxycholic Acid and Ursodeoxycholic Acid

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 377-388

5. Analysis and Interpretation

   1. Front Matter

      Pages 389-389

      PDF

   2. Summaries of the Analyses of Table 1

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 391-398

   3. Interpretation

      • Robert A. Maxwell, Shohreh B. Eckhardt

      Pages 399-416

6. Back Matter

   Pages 417-438

   PDF

This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga­ tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers­ some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view.

• calcium
• clinical research
• drug
• drug discovery
• research
• transplantation

• The Wellcome Research Laboratories, Research Triangle Park, USA

  Robert A. Maxwell

• University of Vermont College of Medicine, Burlington, USA

  Shohreh B. Eckhardt

Policies and ethics